Bruker cuts FY25 EPS view to $1.85-$1.90 from $1.95-$2.05, consensus $1.94

Cuts FY25 revenue view to $3.41B-$3.44B from $3.43B-$3.5B, consensus $3.44B. The company said, “As forecasted, our third quarter revenues and earnings were down year-over-year, primarily due to weaker academic and research instruments demand in the first half of 2025. However, our Q3-25 non-GAAP financial performance was better than expected and represents a meaningful sequential step-up from Q2-25. Nonetheless, due to previous market weakness and EPS dilution from higher share count, we are lowering our FY2025 guidance. For FY2026, our major cost-savings initiatives are progressing well towards the high end of our $100 to $120 million cost-down targets and are expected to deliver significant operating margin expansion and EPS growth in 2026.”